Two major Wisconsin pediatric centers have paused gender‑affirming treatments for minors after Health and Human Services proposed rules to cut Medicare and Medicaid payments to facilities that provide those services; a local pharmacy says it will continue dispensing hormones, and state leaders have moved to challenge the federal guidance in court.
On December 18, Health and Human Services announced a plan to withhold federal Medicare and Medicaid funding from institutions that perform puberty blockers, cross‑sex hormones, or surgical interventions on children. The administration framed the move as a nationwide enforcement step, and it quickly forced hospitals and clinics to reassess how they deliver care to minors. That shift has now reached major pediatric providers in Wisconsin.
After two Colorado hospitals stopped providing gender‑related services to minors, Wisconsin’s largest pediatric centers followed suit. Both Children’s Hospital of Wisconsin and UW Health said they would pause gender‑affirming treatment for patients under 18 while the legal and regulatory dust settles.
Children’s Wisconsin and UW Health, two of the state’s largest pediatric hospitals, have paused gender-affirming care treatment for minors, according to sources associated with both clinics.
The move comes less than a month after U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced newly proposed rules on Dec. 18 that the federal government would deny Medicaid and Medicare payments to hospitals and clinics for all medical interventions if they provide gender-affirming care services for patients 17 and younger. Such a move would virtually shut down any hospital.
The rules specifically would bar Medicaid payments for gender-affirming treatments for minors, remove gender dysphoria from being protected under a federal disability law, and halt manufacturers from marketing breast binders to children and adolescents.
The decisions landed hard in Madison. Governor Tony Evers, who has publicly criticized Republican efforts to limit youth gender care, faces a new political flashpoint in his state. Hospitals say they are acting to protect their institutions and federal funding streams, while critics argue that the changes will deny necessary services to vulnerable families.
Not everyone in Wisconsin is backing the pause. One family pharmacy has explicitly refused to stop dispensing gender‑affirming medications to minors, throwing into relief the split between institutions and individual providers. That disagreement has made Wisconsin a microcosm of the national debate over who should decide medical standards for children.
“Trans kids deserve care. We will continue to provide it. Fitchburg Family Pharmacy will continue dispensing gender-affirming medications for trans and gender-diverse youth with dignity, privacy, and respect. Our commitment to our patients does not change when the landscape does,” the pharmacy wrote on Facebook.
Owner Thad Schumacher underscored that stance with a personal statement that tied his professional position to family ties. “As the father of a trans person, and lifelong healthcare provider, it is extremely important to me that trans patients are able to access the gender affirming care they need. Despite the rules proposed by the Trump Administration, we will continue providing pediatric gender affirming care in person and over telehealth. We will not stop prescribing and dispensing puberty blockers and other hormone therapies to patients of all ages. The federal landscape may change, but my promise will not.”
The Evers administration has joined a multi‑state lawsuit challenging the HHS proposal, turning Wisconsin into a legal battleground for these policies. State attorneys and advocacy groups are already lining up on both sides, and judges will soon be asked to weigh in on whether the federal rules can be enforced while litigation proceeds. That process promises months of uncertainty for families and providers.
From a Republican perspective, the federal action simply enforces a common‑sense line: medical interventions that permanently alter developing bodies deserve rigorous scrutiny and, in many cases, should not be performed on minors. The pause by major hospitals confirms that federal funding is a meaningful lever, and it forces the broader medical community to reckon with long‑term risks and liability questions.
Parents, clinicians, and elected officials will keep clashing over the right balance between access and oversight. Lawsuits will wind their way through courts, pharmacies will make individual choices, and hospitals will try to protect their ability to serve patients without losing federal reimbursements. The outcome in Wisconsin will matter beyond the state; it will shape how the nation handles similar disputes in the months ahead.
